Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
NCT06032026
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Multiple System Atrophy (MSA). The investigators will compare uptake in people with MSA with people with Parkinson disease (PD) and progressive supranuclear palsy (PSP) as well as healthy volunteers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Tauopathies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Pennsylvania
- Last updated on ClinicalTrials.gov
- November 19, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- University of Pennsylvania · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.